- Home
- NCPL vs PHGE Comparison
NCPL vs PHGE Comparison
Compare NCPL & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | PHGE |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 7.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NCPL | PHGE |
|---|---|---|
| Price | $0.46 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 79.6K | ★ 88.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.25 |
| 52 Week High | $8.75 | $8.50 |
Technical Indicators
Market Signals| Indicator | NCPL | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 46.14 |
| Support Level | N/A | $0.41 |
| Resistance Level | $0.62 | $5.99 |
| Average True Range (ATR) | 0.05 | 0.80 |
| MACD | 0.00 | -0.24 |
| Stochastic Oscillator | 2.12 | 8.93 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).